1. Phylogeny  
Activin receptor type‑1B (ACVR1B), commonly referred to as ALK4, belongs to the transforming growth factor‑β (TGF‑β) receptor family and is classified as a type I serine/threonine kinase receptor. Comparative genomic and proteomic analyses have demonstrated that ALK4 is evolutionarily conserved across a broad spectrum of vertebrate species, including mammals, birds, amphibians, and fish. The highly conserved nature of its kinase domain—characterized by conserved motifs such as the glycine‑rich loop, catalytic loop, and activation segment—reflects its essential role in mediating activin signals across different organisms (cui2019perspectivesofsmall pages 1-2, tsuchida2008signaltransductionpathway pages 1-2). Within the kinome, ALK4 is grouped with other type I receptors—most notably ALK5 and ALK7—which share not only high sequence similarity but also a similar overall domain architecture. This subgroup of receptors, derived from an ancestral TGF‑β receptor, has maintained a conserved extracellular ligand‑binding region, a single‑pass transmembrane helix, a regulatory glycine‑serine–rich (GS) domain, and an intracellular serine/threonine kinase domain. The phylogenetic relationship underscores that these receptors have evolved from a common precursor, which is evident in the shared structural and catalytic motifs observed in modern-day vertebrates (katagiri2021accumulatedknowledgeof pages 1-2, cui2019perspectivesofsmall pages 6-7). The presence of orthologs and conserved sequence elements across diverse taxa emphasizes the critical biological functions performed by ALK4 in mediating activin signaling, and it supports the idea that the regulatory mechanisms influencing cell differentiation, proliferation, and tissue morphogenesis via this receptor are ancient and fundamentally important to metazoan biology (tsuchida2008signaltransductionpathway pages 1-2).

2. Reaction Catalyzed  
The principal biochemical reaction catalyzed by ALK4 is the phosphorylation of serine/threonine residues on specific substrate proteins using ATP as the phosphate donor. In the context of activin signaling, ALK4 functions within a heteromeric receptor complex in which activin ligands engage type‑2 receptors (ACVR2A and/or ACVR2B) and lead to subsequent phosphorylation of ALK4’s intracellular region. Initially, the constitutively active serine/threonine kinase activity of the type‑2 receptor phosphorylates residues in the GS domain of ALK4, thereby inducing a conformational change that fully activates the receptor. Subsequently, the activated ALK4 transfers a phosphate group from ATP to target substrates—most notably, the receptor‐regulated Smad proteins, Smad2 and Smad3. These phosphorylation events occur at the C‑terminal regions of the Smads, facilitating their complex formation with Smad4 and eventual translocation into the nucleus where they modulate gene transcription (cui2019perspectivesofsmall pages 2-3, tsuchida2008signaltransductionpathway pages 6-8). The overall kinase reaction can be summarized by the chemical equation:  
  ATP + [protein]-(L‑serine/threonine) → ADP + [protein]-(L‑serine/threonine‑phosphate) + H⁺.  
This phosphotransfer reaction is central to the propagation of the activin signal from the plasma membrane to the nucleus, enabling precise regulation of downstream cellular responses.

3. Cofactor Requirements  
The catalytic activity of ALK4 is strictly dependent on the availability of ATP, which serves as the phosphate donor in the phosphorylation reaction. In addition to ATP, the enzyme requires the binding of divalent metal ions, with magnesium (Mg²⁺) being the principal cofactor. Mg²⁺ ions coordinate with the phosphate groups of ATP, thereby stabilizing the nucleotide and facilitating its proper orientation within the active site of the kinase. This alignment is essential for the efficient transfer of the phosphate moiety to the serine or threonine residues of substrate proteins. The reliance on Mg²⁺ as a cofactor is a common feature among serine/threonine kinases, ensuring that enzymatic activity is maintained under physiological conditions and that the energy from ATP hydrolysis is effectively harnessed during substrate phosphorylation (tsuchida2008signaltransductionpathway pages 6-8, chen2022reductionofactivin pages 15-16).

4. Substrate Specificity  
Once activated, ALK4 exhibits a defined substrate specificity that is central to the fidelity of activin-mediated signaling. The receptor preferentially phosphorylates the receptor-regulated Smad proteins—predominantly Smad2 and Smad3—by targeting serine/threonine residues located within a conserved C‑terminal motif. This selective phosphorylation event is crucial for the formation of functional Smad complexes, as the phosphorylated Smads associate with the common mediator Smad4 and translocate to the nucleus to direct the transcriptional regulation of target genes. Although the precise consensus sequence for substrate recognition by ALK4 has not been delineated in its entirety, biochemical studies consistently indicate that Smad2/3 substrates are preferentially modified by this receptor. The high specificity for these substrates ensures that activin signals are transmitted accurately via the canonical Smad2/3-dependent pathway, thereby orchestrating a variety of downstream cellular processes such as cell proliferation, differentiation, and apoptosis (cui2019perspectivesofsmall pages 2-3, cui2019perspectivesofsmall pages 6-7, olsen2020activinsasdual pages 1-3).

5. Structure  
The three-dimensional architecture of ALK4 is characterized by a modular domain organization that is reflective of its role as a TGF‑β type I receptor. The extracellular portion of ALK4 is composed of a ligand‑binding domain that is enriched in cysteine residues; this arrangement facilitates the formation of disulfide bonds that are critical for maintaining the receptor’s structural integrity and high-affinity binding to activin ligands. Anchored in the plasma membrane by a single‑pass transmembrane helix, the receptor then extends into the cytoplasm where it is composed of two key regions: a glycine‑serine–rich (GS) domain and a serine/threonine kinase domain.  
The GS domain, which is positioned immediately adjacent to the transmembrane segment, serves as a regulatory module essential for receptor activation. This region must be phosphorylated by type‑2 receptors before ALK4 can become fully active. The intracellular kinase domain itself is highly conserved and comprises several critical motifs, including the glycine‑rich loop (which plays a vital role in ATP binding), the catalytic loop (necessary for phosphotransfer), and the activation segment (which modulates enzyme activity upon phosphorylation). An additional important structural feature is the hinge region that connects the N-terminal and C-terminal lobes of the kinase domain; this region forms part of the ATP‑binding pocket and is a key target for small‑molecule inhibitors such as TP‑008. Structural studies, including molecular docking analyses, have underscored that interactions within the hinge region are essential for inhibitor binding, further emphasizing the functional importance of this domain in ALK4’s 3D conformation (cui2019perspectivesofsmall pages 6-7, hanke2020ahighlyselective pages 3-6, tsuchida2008signaltransductionpathway pages 6-8, lee2023activinreceptoralk4 pages 4-6). Overall, the bilobal architecture of the kinase domain—with its characteristic N‑terminal lobe that is primarily involved in ATP binding and a C‑terminal lobe that contains the active site—mirrors the structure of other members of the TGF‑β receptor family and is critical for its catalytic activity.

6. Regulation  
The regulatory mechanisms that control ALK4 activity are multifaceted and occur at both the extracellular and intracellular levels. The process begins with the binding of activin ligands to the receptor’s extracellular domain; this ligand engagement induces the formation of a heteromeric receptor complex in which ALK4 associates with type‑2 receptors such as ACVR2A and ACVR2B. The type‑2 receptors, which are constitutively active kinases, phosphorylate specific serine/threonine residues within the GS domain of ALK4, thereby triggering a conformational change that fully activates its kinase function (cui2019perspectivesofsmall pages 2-3, tsuchida2008signaltransductionpathway pages 1-2).  
In addition to ligand‑induced activation, ALK4 is subject to additional layers of regulation mediated by intracellular adaptor proteins. Proteins containing PDZ domains—commonly referred to as activin receptor–interacting proteins (ARIPs)—bind to ALK4 and facilitate its localization at specific subcellular sites, thus ensuring that the receptor is optimally positioned to engage in signaling complexes. Negative regulatory mechanisms also play a significant role; inhibitory Smads (particularly Smad7) can bind to ALK4 and obstruct further phosphorylation of receptor‑regulated Smads, thereby attenuating activin signaling. Moreover, E3 ubiquitin ligases such as Smurf1 target ALK4 for proteasomal degradation, serving as an important mechanism to curtail aberrant receptor activity (cui2019perspectivesofsmall pages 5-6, tsuchida2008signaltransductionpathway pages 4-6).  
Pharmacologically, several small‑molecule inhibitors have been developed to directly target ALK4 activity. Compounds such as SB‑431542, A‑83‑01, LY‑2157299, GW‑6604, and the dual ALK4/ALK5 inhibitor TP‑008 have been shown to interact with the ATP‑binding pocket of ALK4, thereby preventing its kinase activity and subsequent Smad phosphorylation. The use of these inhibitors in experimental settings has provided valuable insights into the precise role of ALK4 in both physiological and pathological contexts (hanke2020ahighlyselective pages 8-14, chen2022reductionofactivin pages 15-16).

7. Function  
ALK4 is a central mediator of activin signaling and plays a pivotal role in the transmission of extracellular signals to intracellular transcriptional responses. Upon activation by the binding of activin ligands, ALK4 phosphorylates the receptor‑regulated Smad proteins, predominantly Smad2 and Smad3. These phosphorylated Smads subsequently form heteromeric complexes with Smad4 and translocate into the nucleus, where they regulate the transcription of target genes involved in a multitude of cellular processes.  
The biological roles of ALK4 are diverse. In the nervous system, ALK4-mediated signaling has been implicated in the differentiation and survival of neurons, a function that is critical both during development and for the maintenance of adult neural tissue. In addition, ALK4 signaling is involved in hair follicle development and cycling, contributing to skin homeostasis. In the pituitary gland, activin signals conveyed through ALK4 modulate the production of follicle‑stimulating hormone (FSH), which is essential for proper reproductive function. Furthermore, ALK4 plays an important role in wound healing and the repair of damaged tissues by promoting extracellular matrix production—a process that is crucial for tissue remodeling and regeneration.  
Beyond its roles in development and tissue maintenance, ALK4 is also associated with immunosuppression and carcinogenesis. In various cellular models, aberrant activin signaling via ALK4 has been linked to the modulation of immune responses, and dysregulated ALK4 activity can contribute to tumor progression, epithelial‑to‑mesenchymal transition, and metastasis. The dualistic nature of activin signaling via ALK4 is evident in the context of cancer, where the receptor can exert either tumor‑promoting or tumor‑suppressive effects depending on the cellular environment and the composition of the downstream signaling network (cui2019perspectivesofsmall pages 2-3, cui2019perspectivesofsmall pages 6-7, tsuchida2008signaltransductionpathway pages 1-2, olsen2020activinsasdual pages 1-3, lee2023activinreceptoralk4 pages 4-6).  
In summary, ALK4 serves as a critical node in activin signaling, integrating external signals to regulate cellular processes related to development, tissue repair, endocrine function, immune modulation, and oncogenesis.

8. Other Comments  
Experimental studies have extensively utilized chemical probes and small‑molecule inhibitors to investigate the function and regulation of ALK4. Inhibitors such as SB‑431542, LY‑2157299, A‑83‑01, GW‑6604, and the dual ALK4/ALK5 inhibitor TP‑008 have been instrumental in dissecting the role of ALK4 in mediating Smad2/3 phosphorylation and subsequent downstream effects. These compounds have not only provided insights into the molecular mechanisms governing activin signaling but have also highlighted the therapeutic potential of targeting ALK4 in disease contexts including fibrosis and cancer (cui2019perspectivesofsmall pages 5-6, hanke2020ahighlyselective pages 1-3, chen2022reductionofactivin pages 15-16).  
Additionally, studies have shown that downregulation of ALK4—either through pharmacological inhibition or genetic knockdown—can ameliorate pathological tissue remodeling, as demonstrated in models of myocardial ischemia/reperfusion injury where reduced ALK4 signaling was associated with diminished cardiac fibrosis and inflammation. Moreover, alternative splicing of ALK4 mRNA leading to the production of truncated isoforms has been observed in certain tumor types, acting as dominant negative inhibitors that interfere with activin‐induced anti‑proliferative signaling. This intricate balance between full‑length and truncated forms of ALK4 further underscores the complexity of its regulation and its impact on cellular outcomes, particularly in the context of carcinogenesis (cui2019perspectivesofsmall pages 3-5, cui2019perspectivesofsmall pages 6-7).  
These findings emphasize the importance of precise regulatory control over ALK4 activity and have spurred ongoing research into the development of more selective inhibitors that may serve as both valuable research tools and potential therapeutic agents in the treatment of diseases linked to dysregulated activin signaling.

9. References  
1. cui2019perspectivesofsmall pages 1-2  
2. cui2019perspectivesofsmall pages 2-3  
3. cui2019perspectivesofsmall pages 3-5  
4. cui2019perspectivesofsmall pages 5-6  
5. cui2019perspectivesofsmall pages 6-7  
6. tsuchida2008signaltransductionpathway pages 1-2  
7. tsuchida2008signaltransductionpathway pages 4-6  
8. tsuchida2008signaltransductionpathway pages 6-8  
9. tsuchida2008signaltransductionpathway pages 10-11  
10. hanke2020ahighlyselective pages 1-3  
11. hanke2020ahighlyselective pages 3-6  
12. hanke2020ahighlyselective pages 6-8  
13. hanke2020ahighlyselective pages 8-14  
14. hanke2020ahighlyselective pages 14-15  
15. chen2022reductionofactivin pages 15-16  
16. olsen2020activinsasdual pages 1-3  
17. olsen2020activinsasdual pages 5-8  
18. olsen2020activinsasdual pages 13-14  
19. olsen2020activinsasdual pages 14-15  
20. lee2023activinreceptoralk4 pages 1-2  
21. lee2023activinreceptoralk4 pages 4-6  
22. lee2023activinreceptoralk4 pages 14-14  
23. lotinun2012activinreceptorsignaling pages 1-2  
24. szilagyi2022competitionbetweentype pages 3-5  
25. szilagyi2022competitionbetweentype pages 5-9  
26. szilagyi2022competitionbetweentype pages 19-20  
27. oh2000activinreceptorlikekinase pages 2-2  
28. oh2000activinreceptorlikekinase pages 4-5  
29. katagiri2021accumulatedknowledgeof pages 1-2  
30. katagiri2021accumulatedknowledgeof pages 2-4  
31. katagiri2021accumulatedknowledgeof pages 10-11  
32. katagiri2021accumulatedknowledgeof pages 11-13  
33. katagiri2021accumulatedknowledgeof pages 13-13  
34. garridomartin2010characterizationofthe pages 1-2  
35. garridomartin2010characterizationofthe pages 12-15  
36. kroon2015activinreceptorlikekinase pages 1-2

References

1. (cui2019perspectivesofsmall pages 2-3): Xueling Cui, Shumi Shang, Xinran Lv, Jing Zhao, Yan Qi, and Zhonghui Liu. Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (review). Molecular Medicine Reports, 19:5053-5062, Apr 2019. URL: https://doi.org/10.3892/mmr.2019.10209, doi:10.3892/mmr.2019.10209. This article has 41 citations and is from a peer-reviewed journal.

2. (cui2019perspectivesofsmall pages 5-6): Xueling Cui, Shumi Shang, Xinran Lv, Jing Zhao, Yan Qi, and Zhonghui Liu. Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (review). Molecular Medicine Reports, 19:5053-5062, Apr 2019. URL: https://doi.org/10.3892/mmr.2019.10209, doi:10.3892/mmr.2019.10209. This article has 41 citations and is from a peer-reviewed journal.

3. (cui2019perspectivesofsmall pages 6-7): Xueling Cui, Shumi Shang, Xinran Lv, Jing Zhao, Yan Qi, and Zhonghui Liu. Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (review). Molecular Medicine Reports, 19:5053-5062, Apr 2019. URL: https://doi.org/10.3892/mmr.2019.10209, doi:10.3892/mmr.2019.10209. This article has 41 citations and is from a peer-reviewed journal.

4. (hanke2020ahighlyselective pages 1-3): Thomas Hanke, Jong Fu Wong, Benedict-Tilman Berger, Ismahan Abdi, Lena Marie Berger, Roberta Tesch, Claudia Tredup, Alex N. Bullock, Susanne Müller, and Stefan Knapp. A highly selective chemical probe for activin receptor-like kinases alk4 and alk5. ACS Chemical Biology, 15:862-870, Mar 2020. URL: https://doi.org/10.1021/acschembio.0c00076, doi:10.1021/acschembio.0c00076. This article has 23 citations and is from a domain leading peer-reviewed journal.

5. (hanke2020ahighlyselective pages 3-6): Thomas Hanke, Jong Fu Wong, Benedict-Tilman Berger, Ismahan Abdi, Lena Marie Berger, Roberta Tesch, Claudia Tredup, Alex N. Bullock, Susanne Müller, and Stefan Knapp. A highly selective chemical probe for activin receptor-like kinases alk4 and alk5. ACS Chemical Biology, 15:862-870, Mar 2020. URL: https://doi.org/10.1021/acschembio.0c00076, doi:10.1021/acschembio.0c00076. This article has 23 citations and is from a domain leading peer-reviewed journal.

6. (hanke2020ahighlyselective pages 8-14): Thomas Hanke, Jong Fu Wong, Benedict-Tilman Berger, Ismahan Abdi, Lena Marie Berger, Roberta Tesch, Claudia Tredup, Alex N. Bullock, Susanne Müller, and Stefan Knapp. A highly selective chemical probe for activin receptor-like kinases alk4 and alk5. ACS Chemical Biology, 15:862-870, Mar 2020. URL: https://doi.org/10.1021/acschembio.0c00076, doi:10.1021/acschembio.0c00076. This article has 23 citations and is from a domain leading peer-reviewed journal.

7. (olsen2020activinsasdual pages 1-3): O. E. Olsen, H. Hella, Samah Elsaadi, C. Jacobi, E. Martinez-Hackert, and T. Holien. Activins as dual specificity tgf-β family molecules: smad-activation via activin- and bmp-type 1 receptors. Biomolecules, Mar 2020. URL: https://doi.org/10.3390/biom10040519, doi:10.3390/biom10040519. This article has 53 citations and is from a peer-reviewed journal.

8. (tsuchida2008signaltransductionpathway pages 1-2): K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami, and Xueling Cui. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocrine journal, 55 1:11-21, Feb 2008. URL: https://doi.org/10.1507/endocrj.kr-110, doi:10.1507/endocrj.kr-110. This article has 198 citations and is from a peer-reviewed journal.

9. (tsuchida2008signaltransductionpathway pages 4-6): K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami, and Xueling Cui. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocrine journal, 55 1:11-21, Feb 2008. URL: https://doi.org/10.1507/endocrj.kr-110, doi:10.1507/endocrj.kr-110. This article has 198 citations and is from a peer-reviewed journal.

10. (tsuchida2008signaltransductionpathway pages 6-8): K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami, and Xueling Cui. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocrine journal, 55 1:11-21, Feb 2008. URL: https://doi.org/10.1507/endocrj.kr-110, doi:10.1507/endocrj.kr-110. This article has 198 citations and is from a peer-reviewed journal.

11. (chen2022reductionofactivin pages 15-16): Mantian Chen, Yinggang Sun, Qian Wang, and Yigang Li. Reduction of activin receptor-like kinase 4 expression ameliorates myocardial ischemia/reperfusion injury through inhibiting tgfβ signaling pathway. Analytical Cellular Pathology, 2022:1-18, Mar 2022. URL: https://doi.org/10.1155/2022/5242323, doi:10.1155/2022/5242323. This article has 4 citations and is from a peer-reviewed journal.

12. (cui2019perspectivesofsmall pages 1-2): Xueling Cui, Shumi Shang, Xinran Lv, Jing Zhao, Yan Qi, and Zhonghui Liu. Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (review). Molecular Medicine Reports, 19:5053-5062, Apr 2019. URL: https://doi.org/10.3892/mmr.2019.10209, doi:10.3892/mmr.2019.10209. This article has 41 citations and is from a peer-reviewed journal.

13. (cui2019perspectivesofsmall pages 3-5): Xueling Cui, Shumi Shang, Xinran Lv, Jing Zhao, Yan Qi, and Zhonghui Liu. Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (review). Molecular Medicine Reports, 19:5053-5062, Apr 2019. URL: https://doi.org/10.3892/mmr.2019.10209, doi:10.3892/mmr.2019.10209. This article has 41 citations and is from a peer-reviewed journal.

14. (lee2023activinreceptoralk4 pages 4-6): E. Lee, T. Guo, R. Srivastava, Assim Shabbir, and C. Ibáñez. Activin receptor alk4 promotes adipose tissue hyperplasia by suppressing differentiation of adipocyte precursors. The Journal of Biological Chemistry, Nov 2023. URL: https://doi.org/10.1016/j.jbc.2022.102716, doi:10.1016/j.jbc.2022.102716. This article has 6 citations.

15. (lotinun2012activinreceptorsignaling pages 1-2): Sutada Lotinun, R. Scott Pearsall, William C. Horne, and Roland Baron. Activin receptor signaling: a potential therapeutic target for osteoporosis. Current molecular pharmacology, 5 2:195-204, May 2012. URL: https://doi.org/10.2174/1874467211205020195, doi:10.2174/1874467211205020195. This article has 63 citations and is from a peer-reviewed journal.

16. (szilagyi2022competitionbetweentype pages 3-5): Szabina Szófia Szilágyi, Ayelet R. Amsalem-Zafran, Keren E. Shapira, Marcelo Ehrlich, and Yoav I. Henis. Competition between type i activin and bmp receptors for binding to acvr2a regulates signaling to distinct smad pathways. BMC Biology, Feb 2022. URL: https://doi.org/10.1186/s12915-022-01252-z, doi:10.1186/s12915-022-01252-z. This article has 19 citations and is from a domain leading peer-reviewed journal.

17. (szilagyi2022competitionbetweentype pages 5-9): Szabina Szófia Szilágyi, Ayelet R. Amsalem-Zafran, Keren E. Shapira, Marcelo Ehrlich, and Yoav I. Henis. Competition between type i activin and bmp receptors for binding to acvr2a regulates signaling to distinct smad pathways. BMC Biology, Feb 2022. URL: https://doi.org/10.1186/s12915-022-01252-z, doi:10.1186/s12915-022-01252-z. This article has 19 citations and is from a domain leading peer-reviewed journal.

18. (lee2023activinreceptoralk4 pages 1-2): E. Lee, T. Guo, R. Srivastava, Assim Shabbir, and C. Ibáñez. Activin receptor alk4 promotes adipose tissue hyperplasia by suppressing differentiation of adipocyte precursors. The Journal of Biological Chemistry, Nov 2023. URL: https://doi.org/10.1016/j.jbc.2022.102716, doi:10.1016/j.jbc.2022.102716. This article has 6 citations.

19. (lee2023activinreceptoralk4 pages 14-14): E. Lee, T. Guo, R. Srivastava, Assim Shabbir, and C. Ibáñez. Activin receptor alk4 promotes adipose tissue hyperplasia by suppressing differentiation of adipocyte precursors. The Journal of Biological Chemistry, Nov 2023. URL: https://doi.org/10.1016/j.jbc.2022.102716, doi:10.1016/j.jbc.2022.102716. This article has 6 citations.

20. (szilagyi2022competitionbetweentype pages 19-20): Szabina Szófia Szilágyi, Ayelet R. Amsalem-Zafran, Keren E. Shapira, Marcelo Ehrlich, and Yoav I. Henis. Competition between type i activin and bmp receptors for binding to acvr2a regulates signaling to distinct smad pathways. BMC Biology, Feb 2022. URL: https://doi.org/10.1186/s12915-022-01252-z, doi:10.1186/s12915-022-01252-z. This article has 19 citations and is from a domain leading peer-reviewed journal.

21. (tsuchida2008signaltransductionpathway pages 10-11): K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami, and Xueling Cui. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocrine journal, 55 1:11-21, Feb 2008. URL: https://doi.org/10.1507/endocrj.kr-110, doi:10.1507/endocrj.kr-110. This article has 198 citations and is from a peer-reviewed journal.

22. (hanke2020ahighlyselective pages 14-15): Thomas Hanke, Jong Fu Wong, Benedict-Tilman Berger, Ismahan Abdi, Lena Marie Berger, Roberta Tesch, Claudia Tredup, Alex N. Bullock, Susanne Müller, and Stefan Knapp. A highly selective chemical probe for activin receptor-like kinases alk4 and alk5. ACS Chemical Biology, 15:862-870, Mar 2020. URL: https://doi.org/10.1021/acschembio.0c00076, doi:10.1021/acschembio.0c00076. This article has 23 citations and is from a domain leading peer-reviewed journal.

23. (hanke2020ahighlyselective pages 6-8): Thomas Hanke, Jong Fu Wong, Benedict-Tilman Berger, Ismahan Abdi, Lena Marie Berger, Roberta Tesch, Claudia Tredup, Alex N. Bullock, Susanne Müller, and Stefan Knapp. A highly selective chemical probe for activin receptor-like kinases alk4 and alk5. ACS Chemical Biology, 15:862-870, Mar 2020. URL: https://doi.org/10.1021/acschembio.0c00076, doi:10.1021/acschembio.0c00076. This article has 23 citations and is from a domain leading peer-reviewed journal.

24. (katagiri2021accumulatedknowledgeof pages 2-4): Takenobu Katagiri, Sho Tsukamoto, and Mai Kuratani. Accumulated knowledge of activin receptor-like kinase 2 (alk2)/activin a receptor, type 1 (acvr1) as a target for human disorders. Biomedicines, 9:736, Jun 2021. URL: https://doi.org/10.3390/biomedicines9070736, doi:10.3390/biomedicines9070736. This article has 18 citations and is from a peer-reviewed journal.

25. (olsen2020activinsasdual pages 13-14): O. E. Olsen, H. Hella, Samah Elsaadi, C. Jacobi, E. Martinez-Hackert, and T. Holien. Activins as dual specificity tgf-β family molecules: smad-activation via activin- and bmp-type 1 receptors. Biomolecules, Mar 2020. URL: https://doi.org/10.3390/biom10040519, doi:10.3390/biom10040519. This article has 53 citations and is from a peer-reviewed journal.

26. (olsen2020activinsasdual pages 14-15): O. E. Olsen, H. Hella, Samah Elsaadi, C. Jacobi, E. Martinez-Hackert, and T. Holien. Activins as dual specificity tgf-β family molecules: smad-activation via activin- and bmp-type 1 receptors. Biomolecules, Mar 2020. URL: https://doi.org/10.3390/biom10040519, doi:10.3390/biom10040519. This article has 53 citations and is from a peer-reviewed journal.

27. (olsen2020activinsasdual pages 5-8): O. E. Olsen, H. Hella, Samah Elsaadi, C. Jacobi, E. Martinez-Hackert, and T. Holien. Activins as dual specificity tgf-β family molecules: smad-activation via activin- and bmp-type 1 receptors. Biomolecules, Mar 2020. URL: https://doi.org/10.3390/biom10040519, doi:10.3390/biom10040519. This article has 53 citations and is from a peer-reviewed journal.

28. (katagiri2021accumulatedknowledgeof pages 13-13): Takenobu Katagiri, Sho Tsukamoto, and Mai Kuratani. Accumulated knowledge of activin receptor-like kinase 2 (alk2)/activin a receptor, type 1 (acvr1) as a target for human disorders. Biomedicines, 9:736, Jun 2021. URL: https://doi.org/10.3390/biomedicines9070736, doi:10.3390/biomedicines9070736. This article has 18 citations and is from a peer-reviewed journal.

29. (oh2000activinreceptorlikekinase pages 2-2): S. Paul Oh, Tsugio Seki, Kendrick A. Goss, Takeshi Imamura, Youngsuk Yi, Patricia K. Donahoe, Li Li, Kohei Miyazono, Peter ten Dijke, Seongjin Kim, and En Li. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proceedings of the National Academy of Sciences, 97:2626-2631, Mar 2000. URL: https://doi.org/10.1073/pnas.97.6.2626, doi:10.1073/pnas.97.6.2626. This article has 1153 citations.

30. (oh2000activinreceptorlikekinase pages 4-5): S. Paul Oh, Tsugio Seki, Kendrick A. Goss, Takeshi Imamura, Youngsuk Yi, Patricia K. Donahoe, Li Li, Kohei Miyazono, Peter ten Dijke, Seongjin Kim, and En Li. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proceedings of the National Academy of Sciences, 97:2626-2631, Mar 2000. URL: https://doi.org/10.1073/pnas.97.6.2626, doi:10.1073/pnas.97.6.2626. This article has 1153 citations.

31. (garridomartin2010characterizationofthe pages 1-2): Eva M Garrido-Martin, Francisco J Blanco, Africa Fernandez-L, Carmen Langa, Calvin P Vary, Ursula E Lee, Scott L Friedman, Luisa M Botella, and Carmelo Bernabeu. Characterization of the human activin-a receptor type ii-like kinase 1 (acvrl1) promoter and its regulation by sp1. BMC Molecular Biology, 11:51-51, Jun 2010. URL: https://doi.org/10.1186/1471-2199-11-51, doi:10.1186/1471-2199-11-51. This article has 50 citations and is from a peer-reviewed journal.

32. (garridomartin2010characterizationofthe pages 12-15): Eva M Garrido-Martin, Francisco J Blanco, Africa Fernandez-L, Carmen Langa, Calvin P Vary, Ursula E Lee, Scott L Friedman, Luisa M Botella, and Carmelo Bernabeu. Characterization of the human activin-a receptor type ii-like kinase 1 (acvrl1) promoter and its regulation by sp1. BMC Molecular Biology, 11:51-51, Jun 2010. URL: https://doi.org/10.1186/1471-2199-11-51, doi:10.1186/1471-2199-11-51. This article has 50 citations and is from a peer-reviewed journal.

33. (katagiri2021accumulatedknowledgeof pages 1-2): Takenobu Katagiri, Sho Tsukamoto, and Mai Kuratani. Accumulated knowledge of activin receptor-like kinase 2 (alk2)/activin a receptor, type 1 (acvr1) as a target for human disorders. Biomedicines, 9:736, Jun 2021. URL: https://doi.org/10.3390/biomedicines9070736, doi:10.3390/biomedicines9070736. This article has 18 citations and is from a peer-reviewed journal.

34. (katagiri2021accumulatedknowledgeof pages 10-11): Takenobu Katagiri, Sho Tsukamoto, and Mai Kuratani. Accumulated knowledge of activin receptor-like kinase 2 (alk2)/activin a receptor, type 1 (acvr1) as a target for human disorders. Biomedicines, 9:736, Jun 2021. URL: https://doi.org/10.3390/biomedicines9070736, doi:10.3390/biomedicines9070736. This article has 18 citations and is from a peer-reviewed journal.

35. (katagiri2021accumulatedknowledgeof pages 11-13): Takenobu Katagiri, Sho Tsukamoto, and Mai Kuratani. Accumulated knowledge of activin receptor-like kinase 2 (alk2)/activin a receptor, type 1 (acvr1) as a target for human disorders. Biomedicines, 9:736, Jun 2021. URL: https://doi.org/10.3390/biomedicines9070736, doi:10.3390/biomedicines9070736. This article has 18 citations and is from a peer-reviewed journal.

36. (kroon2015activinreceptorlikekinase pages 1-2): Laurie M. G. de Kroon, Roberto Narcisi, Esmeralda N. Blaney Davidson, Mairéad A. Cleary, Henk M. van Beuningen, Wendy J. L. M. Koevoet, Gerjo J. V. M. van Osch, and Peter M. van der Kraan. Activin receptor-like kinase receptors alk5 and alk1 are both required for tgfβ-induced chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells. PLOS ONE, 10:e0146124, Dec 2015. URL: https://doi.org/10.1371/journal.pone.0146124, doi:10.1371/journal.pone.0146124. This article has 45 citations and is from a peer-reviewed journal.